Company

Bank

Analyst

Coverage

Opinion

Wk chg

5/9 cls

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR)

Cowen

Nicholas Bishop

Downgrade

Market perform (from outperform)

-25%

$32.62

Bishop also lowered his target to $36 from $85 after Aegerion reported 1Q14 sales of Juxtapid lomitapide, the company's only product, were $27M in the quarter, up from $1.2M in 1Q13 but below the Street's $33.6M estimate. Aegerion lowered its 2014 revenue guidance to $180-$200M from $190-$210M. The company markets Juxtapid in the U.S. and in the EU as Lojuxta for homozygous familial hypercholesterolemia (hoFH). Bishop lowered his peak U.S. sales estimate to $500M from $900M.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Jefferies

Eun Yang

Upgrade

Buy (from hold)

-8%

$6.67